- Home
- SIGA vs RGNX Comparison
SIGA vs RGNX Comparison
Compare SIGA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- RGNX
- Stock Information
- Founded
- SIGA 1995
- RGNX 2008
- Country
- SIGA United States
- RGNX United States
- Employees
- SIGA N/A
- RGNX N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIGA Health Care
- RGNX Health Care
- Exchange
- SIGA Nasdaq
- RGNX Nasdaq
- Market Cap
- SIGA 515.1M
- RGNX 451.1M
- IPO Year
- SIGA 1997
- RGNX 2015
- Fundamental
- Price
- SIGA $8.90
- RGNX $9.21
- Analyst Decision
- SIGA
- RGNX Strong Buy
- Analyst Count
- SIGA 0
- RGNX 8
- Target Price
- SIGA N/A
- RGNX $28.50
- AVG Volume (30 Days)
- SIGA 511.7K
- RGNX 623.2K
- Earning Date
- SIGA 11-06-2025
- RGNX 11-05-2025
- Dividend Yield
- SIGA 6.88%
- RGNX N/A
- EPS Growth
- SIGA N/A
- RGNX N/A
- EPS
- SIGA 1.14
- RGNX N/A
- Revenue
- SIGA $179,639,422.00
- RGNX $155,782,000.00
- Revenue This Year
- SIGA N/A
- RGNX $260.25
- Revenue Next Year
- SIGA $115.06
- RGNX N/A
- P/E Ratio
- SIGA $7.65
- RGNX N/A
- Revenue Growth
- SIGA 3.86
- RGNX 74.95
- 52 Week Low
- SIGA $4.95
- RGNX $5.04
- 52 Week High
- SIGA $9.62
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- SIGA 61.35
- RGNX 52.85
- Support Level
- SIGA $8.49
- RGNX $9.15
- Resistance Level
- SIGA $9.09
- RGNX $10.08
- Average True Range (ATR)
- SIGA 0.32
- RGNX 0.52
- MACD
- SIGA -0.02
- RGNX 0.03
- Stochastic Oscillator
- SIGA 78.22
- RGNX 44.06
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.